Beyond the chimeric antigen receptor T cells and bispecific antibody duopoly: ex vivo armed T cells for solid tumors - PubMed
3 hours ago
- #T-cell therapy
- #solid tumors
- #immunotherapy
- Monoclonal antibodies dominate immunotherapy, but T-cell-based therapies are advancing.
- CAR-T and bispecific antibodies are key T-cell therapies, but solid tumors require more options.
- Ex vivo armed T cells (EATs) combine antibody targeting with expanded T cells for solid tumors.
- EATs address issues like poor tumor infiltration, immune escape, and treatment toxicities.
- They offer personalized multi-antigen targeting and potential for off-the-shelf therapy.
- Strategies to improve EATs include BsAb optimization, TME modulation, and multi-antigen engagement.
- EATs represent a third way beyond CAR-T and bispecific antibodies, expanding therapeutic paradigms.